What is the initial empiric intraperitoneal antibiotic strategy for suspected PD-associated peritonitis?

What is the initial empiric intraperitoneal antibiotic strategy for suspected PD-associated peritonitis?

• A. Oral antibiotics with no culture obtained
• B. Intraperitoneal vancomycin (or cefazolin) for Gram-positive coverage plus intraperitoneal ceftazidime (or an aminoglycoside) for Gram-negative coverage, started after effluent sample is obtained.
• C. Intravenous antibiotics without effluent culture
• D. Topical antibiotics applied to the exit site only

Answer: (B)

When PD patients develop peritonitis, the goal is to deliver antibiotic therapy directly into the peritoneal cavity with broad initial coverage while we wait for culture results. The best initial plan is to use intraperitoneal antibiotics that target both common Gram-positive and Gram-negative organisms. A typical empiric combination is vancomycin (or cefazolin) for Gram-positive coverage and ceftazidime (or an aminoglycoside) for Gram-negative coverage, started after the effluent sample has been obtained for culture and Gram stain. This approach ensures high peritoneal antibiotic levels quickly and provides broad protection against the organisms most likely to cause PD-associated peritonitis. If cultures later identify a specific pathogen, therapy can be adjusted accordingly. Oral antibiotics without culture data, intravenous antibiotics (without intraperitoneal delivery), or topical exit-site antibiotics do not provide the appropriate intraperitoneal exposure or coverage needed for a suspected peritonitis episode.

When PD patients develop peritonitis, the goal is to deliver antibiotic therapy directly into the peritoneal cavity with broad initial coverage while we wait for culture results. The best initial plan is to use intraperitoneal antibiotics that target both common Gram-positive and Gram-negative organisms. A typical empiric combination is vancomycin (or cefazolin) for Gram-positive coverage and ceftazidime (or an aminoglycoside) for Gram-negative coverage, started after the effluent sample has been obtained for culture and Gram stain. This approach ensures high peritoneal antibiotic levels quickly and provides broad protection against the organisms most likely to cause PD-associated peritonitis. If cultures later identify a specific pathogen, therapy can be adjusted accordingly. Oral antibiotics without culture data, intravenous antibiotics (without intraperitoneal delivery), or topical exit-site antibiotics do not provide the appropriate intraperitoneal exposure or coverage needed for a suspected peritonitis episode.